Previous 10 | Next 10 |
home / stock / rhhby / rhhby articles
Wednesday, Roche Holding AG (OTC:RHHBY) entered into a definitive agreement with Lonza Group Ltd (OTC:LZAGF) (OTC:LZAGY). Under...
On Thursday, the FDA approved BeiGene Ltd’s (NASDAQ:BGNE) approved Tevimbra (tislelizumab-jsgr) as monotherapy for adult patients w...
Tuesday, Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) said the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapeutic ta...
Friday, the FDA accepted and filed Sarepta Therapeutics Inc’s (NASDAQ:SRPT) efficacy supplement to the Biologics License Application (BLA) ...
Wedbush initiated coverage on Monte Rosa Therapeutics Inc (NASDAQ:GLUE), a company focused on developing molecular glue degraders (M...
Tuesday, Repare Therapeutics Inc (NASDAQ:RPTX) announced to regain global development and commercialization rights to camonsertib (RP-350...
HOOKIPA Pharma Inc (NASDAQ:HOOK) will focus its resources on prioritizing the clinical development of a randomized trial for its HB-200 progra...
Friday, the FDA approved Merck & Co Inc’s (NYSE:MRK) Keytruda (pembrolizumab) in combination with chemoradiotherapy (CRT) for F...
In a recent revelation, CNBC’s Mad Money host Jim Cramer disclosed that the financial market values artificial intelligence (AI) technology m...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
7.22%Change Percent:
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
Roche Holding Ltd ADR Website:
– More than 90% of patients had absence of DME after four years in a pre-specified exploratory endpoint – – People treated with Vabysmo sustained vision gains and anatomical improvements, with almost 80% receiving treatment at intervals of three or four months, in an ...
– After four weeks of treatment, CT-996 demonstrated clinically meaningful weight loss of -7.3% (weight loss in placebo -1.2%; p < 0.001) 1 – – Pharmacokinetic data supports a once-daily oral dosing regimen for CT-996 1 – – The safety ...
Remix Therapeutics™ Attains Near-Term Milestone from Roche Collaboration PR Newswire The collaboration leverages Remix's REMaster ™ platform to discover novel drugs for a diverse range of target classes Remix is eligible to receive up to ...